A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
Status: | Terminated |
---|---|
Conditions: | Obesity Weight Loss |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 4/21/2016 |
Start Date: | May 2012 |
End Date: | May 2013 |
A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on
body weight in overweight or obese subjects.
body weight in overweight or obese subjects.
Inclusion Criteria:
- Body Mass Index (BMI) from 30.0 to 39.9 kg/m2, for subjects with no additional co
morbidities;
- BMI from 27 to 39.9 kg/m2, for subjects with co morbidities (i.e. dyslipidemia
defined as high LDL (≥ 160 mg/dL) or high total cholesterol (≥ 240 mg/dL), or
subjects with hypertension)
Exclusion Criteria:
- Systolic blood pressure > 160 mmHg and/or diastolic pressure > 90 mmHg at the
Screening Visit without treatment
- History of use of tobacco or nicotine-containing products 180 days prior to Screening
visit
- Subjects with type 2 diabetes or fasting blood glucose concentration ≥ 126 mg/dL
- History of appetite or weight modifying surgeries/procedures
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials